The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey - 13/12/17
, Shaloo Gupta, MSc b, Caroline Amand, PhD a, Abhijit Gadkari, PhD c, Puneet Mahajan, PhD d, Joel M. Gelfand, MD eAbstract |
Background |
There is a lack of data on the burden of atopic dermatitis (AD) in adults relative to the general population.
Objective |
To characterize the AD burden in adult patients relative to both matched non-AD controls and matched patients with psoriasis in terms of comorbidities, health care resource utilization (HCRU), and costs.
Methods |
Adults (≥18 years) who self-reported a diagnosis of AD or psoriasis and adult non-AD controls were identified from the 2013 US National Health and Wellness Survey. Patients with AD were propensity score–matched with non-AD controls and patients with psoriasis on demographic variables. Patient-reported outcomes were analyzed between matched cohorts.
Results |
Patients with AD had a significantly greater risk for atopic comorbidities, as well as significantly greater HCRU and total cost compared with non-AD controls. The burden of AD was generally comparable to that of psoriasis, although patients with AD reported increased use of emergency room visits compared with patients with psoriasis.
Limitations |
Patient-reported data are susceptible to recall bias and erroneous classification.
Conclusions |
Adult patients with AD reported a substantial disease burden, suggesting an unmet need for more effective AD treatment options.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, burden of disease, comorbidities, disease severity, health care resource utilization, patient-reported outcomes
Abbreviations used : AD, CCI, CI, ER, HCRU, NHWS, OR
Plan
| Supported by Sanofi and Regeneron Pharmaceuticals, Inc. |
|
| Disclosure: Drs Eckert, Amand, and Mahajan are employees of and stockholders in Sanofi. Dr Gadkari is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. Ms Gupta is an employee of Kantar Health, which has received research funding from Sanofi/Regeneron Pharmaceuticals, Inc. Dr Gelfand is an employee of the University of Pennsylvania Perelman School of Medicine, which has received research funding from Sanofi/Regeneron Pharmaceuticals, Inc. In the previous 12 months, Dr Gelfand has served as a consultant for Abbvie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Valeant, and Pfizer Inc, receiving honoraria; he also receives research grants (to the trustees of the University of Pennsylvania) from Abbvie, Eli Lilly, Janssen, Novartis Corp, Regeneron, Sanofi, and Pfizer Inc, and he has received payment for CME work related to psoriasis. Dr Gelfand is also a co–patent holder of Resiquimod for the treatment of cutaneous T-cell lymphoma. |
Vol 78 - N° 1
P. 54 - janvier 2018 Retour au numéro
Article précédent
- An ecological study of skin biopsies and skin cancer treatment procedures in the United States Medicare population, 2000 to 2015
- David M. Wang, Frederick C. Morgan, Robert J. Besaw, Chrysalyne D. Schmults
- Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials
- Patrick Fleming, Aaron M. Drucker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?